Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Should old folks who have lived their lives be allowed to place a huge economic burden on the young by using a disproportionate amount of limited Medicare resources for medical care?
When combined with motivation to provide good care, uncertainty about how to do so for patients who are excluded from key public insurance provisions can give rise to workarounds. Their practical and ethical complexities should be recognized when considering how to best serve immigrant communities.
AMA J Ethics. 2019;21(1):E100-105. doi:
10.1001/amajethics.2019.100.